8.30AM - 5.30PM EST | 5.30AM - 2.30PM PST

8:30 am Virtual Coffee & Networking

8:50 am Chair’s Opening Remarks

Investigating Novel Inflammasome Inhibitors

9:00 am Determining the Mechanism of Action of Inflammasome Inhibitors

  • Rebecca Coll Principal Investigator,
    Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast

9:30 am Exploring the use of Bioluminescent Resonance Energy Transfer to Depict the Mechanism of Action of Novel Inflammasome Inhibitor

  • Pablo Pelegrin Scientific Deputy Director & Principal Investigator, Biomedical Research Institute of Murcia

10:00 am Realizing Multi Inflammasome Small Molecule Inhibitors

  • Anil Goyal Chief Scientific Officer, Immvention Therapeutics

10:30 am Live Q&A

  • Rebecca Coll Principal Investigator,
    Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast
  • Pablo Pelegrin Scientific Deputy Director & Principal Investigator, Biomedical Research Institute of Murcia
  • Anil Goyal Chief Scientific Officer, Immvention Therapeutics

Synopsis

Have the speaker answer your questions

10:50 am Morning Refreshments & Virtual Speed Networking

DISCOVERY STREAM

TRANSLATIONAL STREAM

Establishing which Target & Indication to Go After

Further Analysing the NLRP-3 Inflammasome & the Potential it Holds

11.50 Targeting Ion Channels to Trigger Inflammasome-Dependent Tumor Immunity

Marcelo Hill, Director, Centre for Translational Immunology, Institut Pasteur de Montevideo

12.20 Inflammation at the Heart of Chronic Kidney Disease

Matt Devalaraja, Chief Scientific Officer, Corvidia Therapeutics

 

12.50 Determine Mechanisms of the Inflammasome in Neuropsychiatric Disorders

Giulio Pasinetti, Professor, University of Massachusetts
Medical School

1.20 Live Q&A Session

11.50 Discovering acALY18 – A New Regulator of the NLRP3 Inflammasome

William T. Stewart, Chief Executive Officer, TherimuneX

 

12.20 Targeting the NLRP3 Inflammasome as a Neuroprotective Therapy in Glaucoma

Meredith Gregory-Ksander, Associate Scientist, Schepens Eye Research Institute, Massachusetts Eye &
Ear Hospital

12.50 Targeting GPCR19-P2X7-NLRP3 Axis for Atopic Dermatitis & Alzheimer Disease

SY Seong, Chief Executive Officer, Shaperon

1.20 Live Q&A Session

1:40 pm Networking & Lunch

OUTSIDE NLRP3 – Where do we Stand?

2:30 pm ASC Inhibition in CNS Injury & Disease

  • Robert Keane Professor, Physiology, Biophysics & Neurological Surgery, University of Miami

3:00 pm Recent Insights into NLRP1 and CARD8 Inflammasome Activation

3:30 pm Targeting Multiple Inflammasomes with IC100, a Monoclonal Antibody Against ASC

4:00 pm Live Q&A Session

Synopsis

Have the speakers answer your questions

4:20 pm Networking & Afternoon Refreshments

Delving into the Detail of Cytokine Pathways & Cell Death

4:40 pm Exploring ASC Speck Formation & NET Formation

5:10 pm Inflammasome Signalling & Regulation of Cytokines

  • Kate Schroder Director IMB Centre for Inflammation and Disease Research, The University of Queensland

5:40 pm Live Q&A Session

  • Denisa D. Wagner Professor, Paediatrics, Boston Children’s Hospital
  • Kate Schroder Director IMB Centre for Inflammation and Disease Research, The University of Queensland

Synopsis

Have the speakers answer your questions

6:00 pm Chair’s Closing Remarks